Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats

European Surgical Research

Volumn 47, Issue 1, 2011, Pages 45-51

  Pavlidis, E T ^a   Ballas, K D ^a   Psarras, K ^a   Symeonidis, N G ^a   Koliakos, G ^b   Kouzi Koliakos, K ^b   Rafailidis, S F ^a   Pavlidis, T E ^a   Marakis, G N ^a   Sakantamis, A K ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Angiogenesis; Bevacizumab; Targeted therapy; Vascular endothelial growth factor; Wound healing

Indexed keywords

ANTIOXIDANT; BEVACIZUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; HYDROXYPROLINE; SODIUM CHLORIDE;

ABDOMINAL INJURY; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; HISTOLOGY; INTRAOPERATIVE PERIOD; LAPAROTOMY; MALE; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; RAT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; WISTAR RAT; WOUND CLOSURE; WOUND HEALING;

ABDOMEN; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; ENDOTHELIN-1; HYDROXYPROLINE; INJECTIONS, INTRAPERITONEAL; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 79956192840     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000327970     Document Type: Article

References (49)

1. Thornton AD, Ravn P, Winslet M, Chester K: Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 2006; 93: 1456-1463. (Pubitemid 44893645)
2. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, Simons R, Atabek U: A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62: 707-709.
3. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A: Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009; 66: 999-1013.
4. Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010; 21: 1152-1162.
5. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM: Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010; 11: 373-382.
6. Samaranayake H, Määttä AM, Pikkarainen J, Ylä-Herttuala S: Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther 2010; 21: 381-396.
7. Mabuchi S, Terai Y, Morishige K, Tanabe- Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 7781-7789.
8. Carpini JD, Karam AK, Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010; 13: 43-58.
9. Gounant V, Milleron B, Assouad J, Gligorov J, Lavole A, Wislez M, Brian E, Bazelly B, Grunenwald D: Bevacizumab and invasive procedures: practical recommendations. Rev Mal Respir 2009; 26: 221-226.
10. Mariani P: The safety of perioperative bevacizumab use (in French). J Chir (Paris) 2010; 147(suppl 1):S12-S17.
11. Lazzati V, Zygoń J, Lohsiriwat V, Veronesi P, Petit JY: Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant paclitaxel with bevacizumab. Aesthetic Plast Surg 2010; 34: 796-797.
12. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28: 43-48.
13. Zawacki WJ, Walker TG, DeVasher E, Halpern EF, Waltman AC, Wicky ST, Ryan DP, Kalva SP: Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol 2009; 20: 624-627.
14. Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC: Subcutaneous implantable venous access device erosion through the skin in patients treated with anti- vascular endothelial growth factor therapy: a case series. Anticancer Drugs 2008; 19: 217-219.
15. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17: 1227-1229. (Pubitemid 44673405)
16. Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D: Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010; 101: 180-183.
17. Kim EC, Lee WS, Kim MS: The inhibitory effects of bevacizumab eyedrops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 2010; 51: 4569-4573.
18. 2 expression in alkali-burned mouse cornea. BMB Rep 2009; 42: 800-805.
19. Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlötzer-Schrehardt U, Cursiefen C: Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50: 2095-2102.
20. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers W, Moons L, Stalmans I: Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009; 50: 5217-5225.
21. Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK: Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009; 50: 4653-4659.
22. McNamara DA, Walsh TN, Kay E, Bouchier- Hayes DJ: Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat. Colorectal Dis 2003; 5: 335-341. (Pubitemid 36833822)
23. Okines A, Cunningham D: Current perspective: bevacizumab in colorectal cancer - a time for reappraisal? Eur J Cancer 2009; 45: 2452-2461.
24. Krämer I, Lipp HP: Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32: 1-14. (Pubitemid 46213936)
25. Thornton FJ, Barbul A: Healing in the gastrointestinal tract. Surg Clin North Am 1997; 77: 549-573.
26. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010; 102: 495-499.
27. Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I: Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 2009; 27: 5499-5505.
28. Okines A, del Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer. First BEAT and the randomised phase-III NOI 6966 trial. Br J Cancer 2009; 101: 1033-1038.
29. Mizobe T, Ogata Y, Murakami H, Akagi Y, Ishibashi N, Mori S, Sasatomi T, Shirouzu K: Efficacy of the combined use of bevacizumab and irinotecan as postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 2008; 20: 517-523.
30. Ayral-Kaloustian S, Gu J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K: Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem 2010; 53: 452-459.
31. Bäuerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Gräff A, Kauczor HU, Delorme S, Berger MR: Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 2008; 10: 511-520. (Pubitemid 351657393)
32. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, Wendland MF, McDonald DM, Brasch RC: Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008; 247: 391-399.
33. Raatschen HJ, Fu Y, Rogut V, Simon GH, Sennino B, Wolf KJ, Brasch RC: Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors. Rofo 2010; 182: 133-139.
34. Woodrum C, Nobil A, Dabora SL: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med 2010; 8: 14.
35. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233-242.
36. Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A, Barbet J, Paris F, Kraeber-Bodéré F: Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer 2010; 116(4 suppl):1053-1058.
37. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K, Ohta T: Biodistribution of humanized anti-VEGF monoclonal antibody/ bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 2010; 66: 745-753.
38. Igniatovic D, Aasland K, Pettersen M, Sund S, Chen Y, Spasojevic M, Nesgaard JM: Intraabdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 2010; 200: 270-275.
39. Grenader T, Goldberg A, Verstandig A, Shavit L: Indwelling central venous access port insertion during bevacizumab-based therapy. Anticancer Drugs 2010; 21: 704-707.
40. Gamboa EO, Rehmus EH, Haller N: Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Clin Colorectal Cancer 2010; 9: 55-58.
41. Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB: Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011; 117: 1296-1301.
42. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, Mc- Dermott MW, Parsa AT, Berger MS, Aghi MK: Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2010, E-pub ahead of print.
43. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U: Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15: 1179-1191.
44. Kenmotsu H, Yasunaga M, Goto K, Nagano T, Kuroda JI, Koga Y, Takahashi A, Nishiwaki Y, Matsumura Y: The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 2010; 116: 4597-4604.
45. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, Tellides G, Pober JS, Bender JR, Sadeghi MM: VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010; 107: 408-417.
46. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW: PET imaging of tumor angiogenesis in mice with VEGF-A targeted (86)Y-CHX-A'-DTPA- bevacizumab. Int J Cancer 2010; 128: 920-926.
47. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E: Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosisrelated tumors. Cancer Res 2010; 70: 3483-3493.
48. Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB: A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010; 70: 3269-3277.
49. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW: Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009; 29: 284-290.